CoChat

Antagonism of Azole Activity against Candida albicans following Induction of Multidrug Resistance Genes by Selected Antimicrobial Agents

Open access
Henry, Karl W., Cruz, M. Cristina, Katiyar, Santosh K., Edlind, Thomas D. · 1999 · Antimicrobial Agents and Chemotherapy
Cited by 53

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Antifungal azoles (e.g., fluconazole) are widely used for prophylaxis or treatment of Candida albicans infections in immunocompromised individuals, such as those with AIDS. These individuals are frequently treated with a variety of additional antimicrobial agents. Potential interactions between three azoles and 16 unrelated drugs (antiviral, antibacterial, antifungal, and antiprotozoal agents) were examined in vitro. Two compounds, tested at concentrations achievable in serum, demonstrated an antagonistic effect on azole activity against C. albicans. At fluconazole concentrations two to four times the 50% inhibitory concentration,C. albicans growth (relative to treatment with fluconazole alone) increased 3- to 18-fold in the presence of albendazole (2 μg/ml) or sulfadiazine (50 μg/ml). Antagonism (3- to 78-fold) of ketoconazole and itraconazole activity by these compounds was also observed. Since azole resistance has been correlated with overexpression of genes encoding efflux proteins, we hypothesized that antagonism results from drug-induced overexpression of these same genes. Indeed, brief incubation of C. albicans with albendazole or sulfadiazine resulted in a 3-to->10-fold increase in RNAs encoding multidrug transporter Cdr1p or Cdr2p. Zidovudine, trimethoprim, and isoniazid, which were not antagonistic with azoles, did not induce these RNAs. Fluphenazine, a known substrate for Cdr1p and Cdr2p, strongly induced their RNAs and, consistent with our hypothesis, strongly antagonized azole activity. Finally, antagonism was shown to require a functional Cdr1p. The possibility that azole activity against C. albicans is antagonized in vivo as well as in vitro in the presence of albendazole and sulfadiazine warrants investigation. Drug-induced overexpression of efflux proteins represents a new and potentially general mechanism for drug antagonism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.43.8.1968

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 35

  1. Ausubel F. M. Brent R. Kingston R. E. Moore D. D. Seidman J. G. Smith J. A. Struhl K. Short protocols in molecular biology 3rd ed. 1997 4-22 4-25 John Wiley & Sons Inc. New York N.Y
  2. 10.1128/AAC.38.7.1530 · DOI · Paper page
  3. Blaser J. Joos B. Opravil M. Luthy R. Variability of serum concentration of trimethoprim and sulfamethoxazole during high dose therapy. Infection 21 1993 206 209 · DOI
  4. Boken D. Swindells S. Rinaldi M. Fluconazole resistant Candida albicans. Clin. Infect. Dis. 17 1993 1018 1021 · DOI · Paper page
  5. Edlind T. D. Henry K. W. Katiyar S. K. Genetics of MDR-mediated azole resistance in Saccharomyces cerevisiae abstr. C-154 Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 113 American Society for Microbiology Washington D.C
  6. 10.1128/MCB.17.12.6982 · DOI · Paper page
  7. 10.1007/BF00259685 · DOI · Paper page
  8. Harvey R. P. Isenberg R. A. Stevens D. A. Molecular modifications of imidazole compounds: studies of activity and synergy in vitro and of pharmacology and therapy of Blastomycosis in a mouse model. Rev. Infect. Dis. 2 1980 559 569 · DOI
  9. Henry K. W. Edlind T. D. Induction of multidrug resistance genes in Candida albicans by antimicrobial agents leads to antagonism of azole activity abstr. J-89 Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 476 American Society for Microbiology Washington D.C
  10. 10.1002/(SICI)1097-0061(19980430)14:6<517::AID-YEA250>3.0.CO;2-D · DOI · Paper page
  11. 10.1007/BF00310491 · DOI
  12. Johnson E. M. Richardson M. D. Warnock D. W. In vitro resistance to imidazole antifungals in Candida albicans. J. Antimicrob. Chemother. 13 1984 547 558 · DOI · Paper page
  13. 10.1128/mcb.8.2.664-673.1988 · doi:10.1128/mcb.8.2.664-673.1988
  14. Karcioglu Z. A. El-Yazigi A. Jabak M. H. Choudhury A. H. Ahmed W. S. Pharmacokinetics of azithromycin in trachoma patients: serum and tear levels. Ophthalmology 105 1998 658 661 · DOI
  15. Katiyar S. K. Edlind T. D. Identification of Candida krusei multidrug resistance genes: potential role in azole resistance abstr. C-153 Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 113 American Society for Microbiology Washington D.C
  16. 10.1111/j.1574-6968.1998.tb12910.x · doi:10.1111/j.1574-6968.1998.tb12910.x · Paper page
  17. 10.1128/CMR.10.3.477 · DOI · Paper page
  18. 10.1093/nar/17.22.9488 · DOI · Paper page
  19. Mahajan M. Rohatgi D. Talwar V. Patni S. K. Majahan P. Agarwal D. S. Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis. J. Commun. Dis. 29 1997 269 274
  20. Marcus S. Ziv G. Glickman A. Ozbonfil D. Bartoov B. Klein A. Lincomycin and spectinomycin in the treatment of breeding rams with semen contaminated with ureaplasmas. Res. Vet. Sci. 57 1994 393 394 · doi:10.1016/0034-5288(94)90138-4
  21. Moskopp D. Lotterer E. Concentrations of albendazole in serum, cerebrospinal fluid and hydatidous brain cyst. Neurosurg. Rev. 16 1993 35 37 · DOI
  22. Ng T. T. Denning D. W. Fluconazole resistance in Candida in patients with AIDS: a therapeutic approach. J. Infect. 26L 1993 117 125 · DOI
  23. 10.1128/AAC.38.5.1197 · doi:10.1128/aac.38.5.1197
  24. Petersen D. Demertziz S. Freund M. Schumann G. Individualization of 5-fluorocytosine therapy. Chemotherapy 40 1994 149 156 · DOI
  25. Pfaller M. Epidemiology and control of fungal infections. Clin. Infect. Dis. 19 (Suppl. 1) 1994 S8 S13 · DOI · Paper page
  26. Pohlenz-Zertuche H. O. Brown M. P. Gronwall R. Kunkle G. A. Merrit K. Serum and skin concentrations after multiple-dose oral administration of trimethoprim-sulfadiazine in dogs. Am. J. Vet. Res. 53 1992 1273 1276 · doi:10.2460/ajvr.1992.53.7.1273
  27. Rubio T. T. Miles M. V. Lettieri J. T. Kuhn R. J. Echols R. M. Church D. A. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr. Infect. Dis. J. 16 1997 112 117 · doi:10.1097/00006454-199701000-00033
  28. Sahai J. Gallicano K. Ormsby E. Garber G. Cameron D. W. Relationship between body weight, body surface area and serum zidovudine pharmacokinetic parameters in adult, male HIV-infected patients. AIDS 8 1994 793 796 · doi:10.1097/00002030-199406000-00011
  29. 10.1128/AAC.40.10.2300 · DOI · Paper page
  30. 10.1093/nar/18.10.3091 · DOI · Paper page
  31. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251 1998 252 261 · DOI · Paper page
  32. Seidel E. A. Koenig S. Polis M. A. A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet. AIDS 7 1993 941 945 · doi:10.1097/00002030-199307000-00006
  33. Seth V. Seth S. D. Beotra A. Semwal O. P. D’monty V. Mukhopadhya S. Isoniazid and acetylisoniazid kinetics in serum and urine in pulmonary primary complex with intermittent regimen. Indian Pediatr. 31 1994 279 285
  34. 10.1093/jac/41.3.357 · DOI
  35. Singhal K. C. Varshney M. K. Effect of simultaneous isoniazid administration on pharmacokinetics parameters of pyrazinamide. J. Indian Med. Assoc. 89 1991 227 229

Cited by

Metadata

Authors
Henry, K. W., Cruz, M. C., Katiyar, S. K., & Edlind, T. D.
Venue
Antimicrobial Agents and Chemotherapy
Published
1999-08
Volume
43
Issue
8
Pages
1968-1974
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2133769209
Cited by
53
References
8
FWCI
2.10
Type
journal article
Language
en
Open access
green
Licence
journals.asm.org/non-commercial-tdm-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.